What should I know about Sobi?
Sobi (Swedish Orphan Biovitrum) is a Swedish biopharmaceutical company, headquartered in Stockholm, that develops and sells medicines for rare diseases. Its 2026 company announcement describes about 2,000 employees across Europe, North America, the Middle East, Asia and Australia. It reports revenue in three areas: haematology, immunology and specialty care. Revenue for 2025 was about SEK 28 billion. Sobi shares are listed on Nasdaq Stockholm under the ticker SOBI.
What are Sobi's main drugs?
Sobi's growth is led by what it calls its strategic portfolio. In the second quarter of 2026, Doptelet, used for low platelet counts, brought in SEK 1,628 million. Altuvoct, a haemophilia A treatment, made SEK 1,554 million, up from SEK 627 million a year before. Kineret, an immune-related treatment, made SEK 861 million, and Gamifant, for a rare immune condition called HLH, made SEK 794 million. The strategic portfolio as a whole grew 53% at constant exchange rates.
What is Sobi currently developing?
Sobi's Q2 2026 report highlights positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad, a candidate gout treatment. It also reports that NASP, another potential gout treatment, received a US Complete Response Letter relating to manufacturing, with a path to resubmission. Sobi's announcement ahead of the congress lists data on its medicines in PNH, ITP, HLH and myelofibrosis planned for the European Hematology Association congress.
Is Sobi publicly traded, and how big is it?
Yes. Sobi is listed on Nasdaq Stockholm under the ticker SOBI. A market-data page showed a market capitalisation of about SEK 134 billion on 9 October 2026. Revenue in the second quarter of 2026 was SEK 7,842 million, up 27% from SEK 6,175 million a year earlier, according to its Q2 report. Sobi now expects revenue growth in the mid-to-high teens percent at constant exchange rates for 2026.